Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Li Kang Biomedical Co's Enterprise Value is NT$1,101.6 Mil.
Li Kang Biomedical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-237.4 Mil. Therefore, Li Kang Biomedical Co's EV-to-FCF for today is -4.64.
The historical rank and industry rank for Li Kang Biomedical Co's EV-to-FCF or its related term are showing as below:
ROCO:6242'
s EV-to-FCF Range Over the Past 10 Years
Min: -147.42 Med: 10.23 Max: 1742.52
Current: -4.63
During the past 13 years, the highest EV-to-FCF of Li Kang Biomedical Co was 1742.52. The lowest was -147.42. And the median was 10.23.
ROCO:6242's EV-to-FCF is ranked worse than 100% of 569
companies
in the Travel & Leisure industry
Industry Median: 15.33
vs ROCO:6242: -4.63
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Li Kang Biomedical Co (ROCO:6242) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Li Kang Biomedical Co's PE Ratio (TTM) for today is calculated as:
Li Kang Biomedical Co's share price for today is NT$35.95.
Li Kang Biomedical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.630.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6242 vs BKNG, ABNB, RCL: EV-to-FCF Comparison
For the Travel Services subindustry, Li Kang Biomedical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Li Kang Biomedical Co EV-to-FCF vs Travel & Leisure Industry
For the Travel & Leisure industry and Consumer Cyclical sector, Li Kang Biomedical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Li Kang Biomedical Co's EV-to-FCF falls into.
Li Kang Biomedical Co's current Enterprise Value is NT$1,101.6 Mil.
Li Kang Biomedical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-237.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Li Kang Biomedical Co (ROCO:6242) has a EV-to-FCF of -4.64 as of Jul. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Li Kang Biomedical Co and its competitors. According to the industry distribution chart, Li Kang Biomedical Co ranks #999999 out of 569 companies in the Travel & Leisure industry.
Is Li Kang Biomedical Co's EV-to-FCF too high?
Li Kang Biomedical Co's current EV-to-FCF is -4.64. Based on the distribution chart, Li Kang Biomedical Co ranks #999999 out of 569 companies in the Travel & Leisure industry, which is in the bottom quartile relative to peers. Overall, Li Kang Biomedical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Li Kang Biomedical Co's EV-to-FCF compare to BKNG and ABNB?
According to the Travel & Leisure industry distribution chart, Li Kang Biomedical Co ranks #999999 out of 569 companies for EV-to-FCF. This places Li Kang Biomedical Co in the lower half of its industry. The industry median EV-to-FCF is 15.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Travel & Leisure company?
The median EV-to-FCF among Travel & Leisure companies is 15.33, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Li Kang Biomedical Co and its competitors. For the Travel & Leisure industry, the median EV-to-FCF is 15.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Li Kang Biomedical Co's current EV-to-FCF is -4.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Li Kang Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Li Kang Biomedical Co (ROCO:6242) is currently considered Fairly Valued. The stock's GF Value™ is NT$38.97, compared to a current price of NT$35.95 — trading 7.7% below its estimated fair value. The current EV-to-FCF is -4.64. Li Kang Biomedical Co's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Li Kang Biomedical Co (ROCO:6242), the current EV-to-FCF is -4.64 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Li Kang Biomedical Co (ROCO:6242) Overvalued in 2026?
Based on GuruFocus' analysis, Li Kang Biomedical Co stock appears to be undervalued.
The current stock price of NT$35.95 is trading 7.7% below its estimated GF Value™ of NT$38.97.
GuruFocus considers Li Kang Biomedical Co to be Fairly Valued.
Key valuation signals for ROCO:6242:
EV-to-FCF: -4.64
GF Value™: NT$38.97 vs. price of NT$35.95 (7.7% below fair value)
No single metric tells the full story. See the ROCO:6242 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Li Kang Biomedical Co Ltd is a Taiwan based company engages in tourism factory businesses, telemarketing, as well as the manufacturing and sales of cosmetics and hygienic drinks.
81GF Score
Get the complete analysis for ROCO:6242
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6242 has been successfully added to your 
